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Abstract
Background: Epidemiological data suggest that the male gender is one of the risks factors for the development of
Parkinson Disease (PD). Also, differences in the clinical manifestation and the course of PD have been observed between
males and females. However, little is known about the molecular aspects underlying gender-specificity in PD. To address this
issue, we determined the gene expression profiles of male and female dopamine (DA) neurons in sporadic PD.
Methodology/Principal Findings: We analyzed Affymetrix-based microarrays on laser microdissected DA neurons from
postmortem brains of sporadic PD patients and age-matched controls across genders. Pathway enrichment demonstrated
that major cellular pathways involved in PD pathogenesis showed different patterns of deregulation between males and
females with more prominent downregulation of genes related to oxidative phosporylation, apoptosis, synaptic
transmission and transmission of nerve impulse in the male population. In addition, we found upregulation of gene
products for metabolic processes and mitochondrial energy consumption in the age-matched male control neurons. On the
single cell level, selected data validation using quantitative Real-Time (qRT)-PCR was consistent with microarray raw data
and supported some of the observations from data analysis.
Conclusions/Significance: On the molecular level, our results provide evidence that the expression profiles of aged normal
and PD midbrain DA neurons are gender-specific. The observed differences in the expression profiles suggest a disease bias
of the male gender, which could be in concordance with clinical observations that the male gender represents a risk factor
for sporadic PD. Validation of gene expression by qRT-PCR supported the microarray results, but also pointed to several
caveats involved in data interpretation.
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Introduction
Parkinson disease (PD) is a severe neurological disorder of
unknown etiology characterized by progressive loss of substantia
nigra (SNc) dopaminergic (DA) neurons with the formation of
Lewy bodies in the central, peripheral and enteric nervous systems
[1]. PD clinically manifests in resting tremor, rigidity, bradykinesia
and a wide array of subtler non-motor symptoms such as
depression, fatigue, sleep disturbances and autonomic dysfunction.
Aside of age, the male gender could be an additional risk factor
for the development of PD as suggested from multiple epidemi-
ological studies [2,3,4,5]. Despite high variability between these
studies, it appears that men seem to develop about 1.5 times more
sporadic PD than women. This, however, only referred to people
in Western populations, since gender did not play a role in PD
patients with Asian ethnicity [2,5].
Additional evidence for a gender effect stems from clinical
studies, which reported gender-linked differences in the age of
onset and symptomatology of PD. For example, it was found that
women developed PD later than men (2.1 years) and presented
more frequently with ‘‘benign’’, tremor-dominant phenotype of
the disease, suggesting that at least the initial clinical stages of PD
might be milder in the female population [6]. However, other
studies found faster disease progression in East Asian women with
PD [7] or a difference at the later stages of disease [8,9]. Despite
discrepancies between these reports there appears to be a gender
difference in the clinical presentation of PD.
The reasons for variations between genders in PD are not clear,
but it is suggested that they are at least in part a consequence of
genetic factors [2,10]. A recent study analyzed the gene expression
profile of DA neurons isolated by laser capture microscopy (LCM)
from postmortem brains of normal subjects and patients affected
with sporadic PD [11]. The authors reported a broad gender-
based difference in gene expression that supported the notion that
males are predisposed to PD. Similarly, we recently documented
the expression profiles of laser microdissected (LMD) SNc DA
neurons from 10 PD and 9 control cases and found dysregula-
tion of gene expression in all major pathways relevant to PD
pathogenesis [12].
We now extended this study by conducting a comparable
gender analysis in our cohort. Altogether, we found differential
gene expression in both males and females with distinct patterns of
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prominent downregulation of genes relevant to oxidative phospor-
ylation, apoptosis, synaptic transmission and transmission of nerve
impulse in the male population. By comparing the expression
profiles of neurons between the normal control groups, we found
that males had an enrichment of upregulated genes that are
related to many aspects of cellular homeostasis including
mitochondrial energy consumption. These data suggest a bias of
the male gender towards PD on the molecular level and also could
support some of the clinical observations that disease progression
and presentation are gender-specific.
Materials and Methods
Subjects and Affymetrix-Based Microarrays
A detailed description of the subjects and materials used for this
study can be found in our previous study [12] and Table S1. The
patients formed the following groups: 3 females in each group of
controls and sporadic PD patients, 6 male subjects in the control,
and 7 male subjects in the PD group. SNc DA neurons were
isolated by LMD using a LEICA AS LMD apparatus, and RNA
isolation, amplification and hybridization to the HU-133A arrays
(Affymetrix, Santa Clara, CA) were done according to published
protocols [13]. Microarray raw data and details about subjects are
publicized at the National Brain Databank webpage (http://
national_databank.mclean.harvard.edu/brainbank) and partially
summarized in Table S1.
Data Analysis
Data were analyzed using 3-way analysis of variance (ANOVA)
and significance analysis of microarrays (SAM) procedure after
removing a batch effect as described previously [12]. All
differentially expressed genes for the gender analysis were derived
from SAM and match the criteria of a false discovery rate (FDR)
,5% and p-values ,0.01 (stringent conditions) or ,0.05 (relaxed
conditions). Six different lists were compared for both conditions
(details are provided in Tables S2 and S3): all PD patients versus all
control cases for ANOVA and SAM (allN_allPD), male control
cases versus male PD patients (mN_mPD; mPD), female control
cases versus female PD patients (fN_fPD; fPD), control male versus
control female cases (mN_fN) and male versus female PD patients
(mPD_fPD).
The enrichment-based, pathway-level comparative computa-
tional analysis was largely done according to previously published
protocols [12]. Briefly, using in-house software WPS and a
Pathway Pattern Extraction Pipeline [14] based on a one-sided
Fisher exact test, desired gene lists were computed for their
enrichment levels using different functional categories including
BioCarta pathways, KEGG pathways, or a Gene Ontology (GO-
BP) terms. The enrichment levels were then compared amongst
these lists in such a way that common or uniquely enriched
pathways or terms could be identified. In particular, to test for
male- or female-specific PD pathways we established lists that
featured only genes that were enriched in mPD or fPD and
allN_allPD lists. Based on these lists we created Gene-Term
Association Networks (GTAN) that allowed us to further delineate
single PD-relevant, male-specific transcripts that are common to
two or more major pathways.
In addition to the computational analysis, clustering of probesets
was based on our extensive lists of genes previously described as
deregulated in PD, and which include a wide spectrum of cellular
pathways and processes [12]. This also included a recently
published manuscript providing a cross-study analysis of micro-
array data on PD [15] and available online resources, such as
https://ncascr.griffith.edu.au/pdreview/2008/ and www.pdgene.
org.
TaqManH Real-Time PCR Assay Validation
Validation of gene expression was performed using TaqManH
quantitative Real-Time PCR (qRT-PCR) Gene Expression Assays
and the 7900HT Real-Time PCR System (Applied Biosystems,
Foster City, CA) for the same 14 genes as described in [12]. The
list was extended with three additional male control and PD as
well as two female controls and three female PD samples (Table
S1). Note that for the male samples C10, C11, PD11 and PD14
and the female sample PD13 no microarray data are available.
RNA was isolated from approx. 300 laser-microdissected neurons
using the mirVANA
TM miRNA Isolation Kit (Ambion, Austin,
TX) and RNA quality was determined by determining the
260/280 ratios using nanodrop OD measurements (Table S1).
cDNAs were generated in a 25 ml reverse transcription reaction
with 30–60 ng of total RNA using the High Capacity cDNA
Archive Kit and protocol (Applied Biosystems, PN 4322169) and
subjected to a 10-cycle PCR amplification followed by qRT-PCR
reaction using the manufacturer’s TaqManH PreAmp Master Mix
Kit Protocol (Applied Biosystems, PN 4366127). Three replicates
per sample were assayed for each gene in a 384-well format plate.
For data normalization, GUSB was used as endogenous control
gene and gene expression PD versus control was calculated
according to the 2
2DCt method by Livak and Schmittgen [16].
Results
The analysis of the gene expression profiles followed similar
strategies as previously published [12]. Interestingly, gender
analysis based on 3-way ANOVA with FDR10 did not reveal
differentially expressed genes in fPD. However, we observed
striking gender differences using SAM analysis. The SAM list with
FDR5 and p-values ,0.01 (allN_allPD) was highly overlapping
with our previous ANOVA FDR10 list (Figure S1) and reflected
the ‘‘stringent analysis condition’’, whereas the FDR5 list with
p-values of ,0.05 list was regarded as ‘‘relaxed condition’’.
Altogether, the gender analysis was based on six different gene lists
as described in Material and Methods and a ‘‘Merged Matrix’’
(Tables S2 (p,0.01) and S3 (p,0.05)).
Distribution of Differentially Expressed Genes
The stringent SAM list (FDR5, p,0.01) comprised a total of
2214 deregulated probesets between all control and all PD samples
(Table S2, Figure 1) with similar distribution of up- and
downregulated genes (952 and 1262, respectively) as seen with
ANOVA. Also consistent with ANOVA, we found more
downregulated (642) than upregulated (53) genes when the cut-
off was set at .1.5 fold difference, with downregulation reaching
as high as 11 fold, while only six genes exceeded a 2 fold
upregulation (the maximum being at 3.4 fold). The distribution of
differentially expressed genes within and across the gender groups
showed more up- than downregulation. However, when the cut-off
was set at .1.5 fold difference, all groups except of mN_fN had
more genes down- than upregulated. This was especially obvious
for mPD, in which only seven from 509 genes were .1.5 fold
upregulated, in contrast to 112 out of 634 genes in fPD (four genes
with .3.0 fold). Interestingly, we observed only a moderate
downregulation (14 probesets with 8.1.5 fold), but a striking
upregulation of genes (92 probesets, 63.1.5 fold) in normal
control neurons from males when compared to females (mN_fN)
and the majority of these genes were downregulated in fPD
(Figure 2A).
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genes were present in all groups, 14 genes overlapped between
mPD and mN_fN, 53 genes overlapped between fPD and mN_fN,
and 81 probesets (3.7% of all deregulated genes) were present in
both mN_mPD and fN_fPD (Figure 1, Table S2). When we
directly compared the probesets between the mPD and fPD lists,
we found only four overlapping genes (Table S2). Thus, the
overwhelming number of genes was dysregulated in either females
or males, while only a relatively small number overlapped between
both groups. Interestingly, the majority of the gender-overlapping
genes were simultaneously up- or downregulated in males and
females, while only a small subset of genes was differentially
expressed (Figure 2B, Table S2). Moreover, just 13 of these
probesets related to PD pathogenic pathways and the majority of
them were downregulated (Table 1). It should be noted that from
the allN_allPD group we found 1223 differentially expressed genes
that did not appear in either gender and some of them were part of
gene clusters in all the PD-associated pathways (Figure 1, Table
S2). Taken together, these data indicate that dysregulated gene
expression seems to be gender-specific.
We also analyzed gene distributions in the SAM FDR5 p,0.05
gene lists. As expected, in most groups the overall number of
deregulated probesets increased, but the distributions of genes
largely remained the same (details are provided in Figure S2 and
Table S3). Interestingly, there was no major change in numbers of
deregulated genes in the mN_fN group, while the amount of
probesets that did not appear in either gender decreased about
2-fold (allN_allPD genderless). Also, the number of probesets that
were present in both mN_mPD and fN_fPD increased unpro-
portionally to 610 (18% of all deregulated genes). Despite these
differences, the more relaxed SAM analysis also pointed to gender-
specific deregulation of gene expression.
Gender-Specific Gene Expression in Normal DA Neurons
Prior to the analysis of gene expression profiles related to PD,
we investigated whether gender-specific gene expression occurred
in normal DA neurons. The most prominent observation was that,
relative to females, in normal male neurons only 14 genes were
downregulated, while 92 genes were upregulated (Figure 1,
Figure 2A, Table S2). GO-BP enrichment analysis revealed that
these upregulated genes are involved in many aspects of cellular
homeostasis (Table S4) that also included some key molecules
related to mitochondrial processes, such as glutathion S-transferase
theta 1 (GSTT1), potassium intermediate/small conductance
calcium-activated channels (KCNN3), NADH dehydrogenase
(ubiquinone) 1 subcomplex (NDUFC1), S100 calcium binding
protein A1 (S100A1), and solute carrier family 11 (proton-coupled
divalent metal ion transporters) member 2 (SLC11A2). The
majority of the upregulated genes were simultaneously downreg-
ulated in female PD alone (Figure 2A, Table 2), including several
genes that are associated with pathways related to PD pathogen-
esis such as ST13, MAPT, XPO1, SLC11A2, DNAJC7, KCNN3,
Figure 1. Distribution of gene expression profiles for all groups based on FDR5 p,0.01 analysis. Genes were computationally analyzed
(see Material and Methods for details) and summarized schematically. The groups are as follows: allN_allPD compares all normal versus all PD
samples; mN_fN compares control males versus control females; mN_mPD compares control males versus male PD; fN_fPD compares control females
versus female PD; the overlapping groups indicate the number of genes that are found in several respective groups. Bars represent numbers of up- or
downregulated genes in each group for total genes or after setting the cut-off of differential gene expression at .1.5 fold.
doi:10.1371/journal.pone.0008856.g001
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probesets that overlapped in the mN_fN and fPD gene lists
(Figure 1). In contrast, the five genes present in all three gene lists
and those that overlapped within the mN_fN and mPD groups
(Figure 1, Table S2) did not seem to have any obvious PD-
associated functions.
Enrichment-Based Pathway-Level Comparative Analysis
We next used enrichment-based pathway-level comparative
analysis [12,14] to cluster genes according to pathways of
biological function. In all analyses (Biocarta, KEGG, GO-BP,
GSEA) we observed that female and male transcripts clustered
around specific terms (Figures S3, S4, and S5), which prompted
us to generate enrichment levels only for those terms that are
enriched in allN_allPD and mPD or allN_allPD and fPD lists
(Figures S4 and S5). In both GO-BP and GSEA analysis we found
a prominent enrichment of terms in mPD, but not in fPD. In
addition, when we used the GO-BP terms to establish Gene-Term
Association Networks pinpointing genes that are enriched in
pathways relevant to PD, we found a set of genes in mPD that
were associated with two or more of the following terms: Oxidative
phosphorylation, apoptosis, synaptic transmission, and transmis-
sion of nerve impulse (Figure 3). These results indicated a bias of
some key molecules in PD pathogenesis, such as SNCA, SOD1,
TGFB2, IFNG, NDUFS3, NF1, PPARD, and KRAS towards the
male gender. Similar results were also obtained when the gene lists
were analyzed under the more relaxed criteria (p,0.05) (Figure
S6). When comparing the data from both stringent and relaxed
conditions there was an increased enrichment of terms in both
mPD and fPD with higher variation in the female group and more
consistency with allN_allPD in the male PD group (Figure S6a). In
all analyses, there was a consistent strong enrichment of pathways
relevant to PD pathogenesis including oxidative phosphorylation,
synaptic transmission, and transmission of nerve impulse in mPD
(Figure S6b – d).
Gender-Specific Gene Expression in PD DA Neurons
Although the comparative pathway-level analysis demonstrated
a dominant PD-specific enrichment only in mPD, closer inspection
of the gene lists showed a more complex picture. Assessment of the
lists according to those pathways that directly correlate with PD
pathogenesis (Table S5) revealed that in all pathways gene groups
were dysregulated in both mPD and fPD (Figure 4). Interestingly
however, and consistent with the data for all probesets (Figure 1,
Table S2), the majority of these genes were specific to either male
or female PD and there was little overlap between both genders.
These results further indicated that deregulated gene expression
was gender-specific. To confirm this observation, we additionally
analyzed our data set by focusing on single genes or clusters of
genes similarly to our previous report [12] taking in account both
the stringent (FDR5 p,0.01) and the relaxed (FDR5 p,0.05)
analysis criteria.
PARK Genes
A prominent finding in the stringent data analysis was
downregulation of several genes from the PARK gene family in
male PD alone (Table 3), such as PARK1 (SNCA), PARK6
(PINK1), and PARK7 (DJ-1), which are linked to familial forms of
the disease. However, when the data were analyzed under the
more relaxed conditions, only PARK7 together with UCHL1 were
down-regulated in the males alone, while downregulation of
ATP13A2 and RIMS3 was restricted to females. Interestingly, in
both analysis conditions there were no disease or gender-specific
differences in the expression of Parkin.
Deregulation of Cellular Compartments
The microarrays revealed a complex picture of gene deregu-
lation associated with extrinsic and intrinsic forms of apoptosis,
mitochondrial function, protein degradation pathways, synapse
and cytoskeleton, as well as growth factors, neurotransmitter
receptors and ion channels (Table S5). According to our previous
observations, there was an upregulation of genes involved in
signaling pathways related to extrinsic apoptosis and this was
particularly prominent in fPD. A more complex picture was
observed for genes related to mitochondrial function with a
mixed pattern of mostly downregulated gene expression in
both female and male PD. Noticeable differences could be
observed for protein phosphatase and kinase subunits that were
Figure 2. Distribution of overlapping gene expression profiles
in normal controls and PD based on FDR5 p,0.01 analysis. (A)
Heatmaps of those probesets that are expressed in both normal male
(mN) and female (fN) DA neurons (first column, mN_fN) in comparison
with all other groups (see Table S2 for details). Values shown in the heat
maps are log(ratio) with red for upregulated and green for down-
regulated genes. A larger subset of the upregulated genes is
downregulated in fPD (second column), but not in mPD (fifth column).
(B) Heatmap of those probesets that are expressed in both female
(fN_fPD) and male (mN_mPD) PD DA neurons (first and fourth column)
in comparison with all other probesets (see Table S2 for details). The
majority of the genes are simultaneously up- or downregulated in both
genders, while a small subset of genes is differentially expressed. In
addition, levels of gene expression of the overlapping genes are similar
in both genders. Note: allN_allPD A3W depicts probesets from the
previously published ANOVA FDR10 gene list [12].
doi:10.1371/journal.pone.0008856.g002
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Gene Symbol GenBank ID Description allN_allPD fPD mPD mN_fN mPD_fPD
ATP5G3 NM_001689 ATP synthase H+ transporting, mitochondrial F0 complex
subunit C3
22.25 22.17 22.94 0 0
ATP6V1E1 NM_001696 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 23.57 24.76 23.23 0 0
CHRNA4 NM_000744 cholinergic receptor, nicotinic, alpha 4 1.25 1.4 1.22 0 0
CLTC NM_004859 clathrin, heavy chain (Hc) 21.33 25.56 23.12 0 0
COX7C NM_001867 cytochrome c oxidase subunit VIIc 22.90 22.56 23.64 0 0
DRD2 NM_016574 dopamine receptor D2 1.26 1.33 1.32 0 0
NDUFB2 NM_004546 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 2 23.39 22.22 23.70 0 0
PRKACB NM_207578 protein kinase cAMP-dependent catalytic beta 22.44 1.35 22.70 0 0
SLC35A1 NM_006416 solute carrier family 35 (CMP-sialic acid transporter) member A1 21.49 21.79 21.37 0 0
SLC6A1 NM_003042 solute carrier family 6 (neurotransmitter transporter GABA),
member 1
21.67 21.85 21.56 0 0
TIMM44 NM_006351 translocase of inner mitochondrial membrane 44 homolog
(yeast)
0 21.49 1.26 0 0
UQCRH NM_006004 ubiquinol-cytochrome c reductase hinge protein 22.94 23.45 22.63 0 0
ZNF606 NM_025027 zinc finger protein 606 1.31 1.4 1.27 0 0
doi:10.1371/journal.pone.0008856.t001
Table 2. PD-associated genes present in mN_fN (FDR5, p,0.01).
Gene Symbol GenBank ID Description allN_allPD fPD mPD mN_fN mPD_fPD
AKAP8L NM_014371 A kinase (PRKA) anchor protein 8-like 0 1.54 0 -1.41 0
APBA2 NM_005503 amyloid beta (A4) precursor protein-binding, family A, member
2( X 1 1 - l i k e )
23.23 27.69 0 3.14 0
DDX11 XM_001124814 DEAD/H box polypeptide 11 1.31 0 1.27 1.26 0
DIDO1 NM_080797 death inducer-obliterator 1 0 0 0 1.25 0
DNAJC7 NM_003315 DnaJ (Hsp40) homolog subfamily C member 7 21.67 22.70 0 1.77 0
DNM2 NM_004945 dynamin 2 0 0 0 1.36 0
FOXO3 NM_201559 forkhead box O3 0 23.45 0 2.93 0
GSTT1 NM_000853 glutathione S-transferase theta 1 0 21.61 0 1.61 0
KCNN3 NM_170782 potassium intermediate/small conductance calcium-activated
channel subfamily N
0 21.92 0 1.93 0
MAPK6 NM_002748 mitogen-activated protein kinase 6 0 22.56 0 2.38 0
MAPT NM_016841 microtubule-associated protein tau 0 250 3 . 1 5 0
MICAL2 NM_014632 microtubule associated monoxygenase calponin and LIM domain
containing 2
0 001 . 2 3 0
NDUFC1 NM_002494 NADH dehydrogenase (ubiquinone) 1 subcomplex unknown 1 21.72 22.56 0 1.88 0
PPP2R5E NM_006246 protein phosphatase 2 regulatory subunit B’ epsilon isoform 0 0 0 1.40 0
S100A1 NM_006271 S100 calcium binding protein A1 0 0 0 1.49 0
SLC11A2 NM_000617 solute carrier family 11 (proton-coupled divalent metal ion
transporters) member 2
0 001 . 6 8 0
SLC35E3 NM_018656 solute carrier family 35 member E3 0 0 0 21.56 0
SOX4 NM_003107 SRY (sex determining region Y)-box 4 1.42 0 0 21.78 0
ST13 NM_003932 suppression of tumorigenicity 13 (Hsp70 interacting protein) 21.67 21.67 0 1.52 0
STX8 NM_004853 syntaxin 8 0 21.96 0 1.88 0
TNS1 NM_022648 tensin 1 24.54 26.25 0 3.99 0
TSPAN31 NM_005981 tetraspanin 31 0 0 0 1.35 0
XPO1 NM_003400 exportin 1 (CRM1 homolog, yeast) 21.51 21.78 1.46 21.33 0
ZER1 NM_006336 zer-1 homolog (C. elegans) 0 21.75 0 1.60 0
doi:10.1371/journal.pone.0008856.t002
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downregulation of ATP synthase/H+ transporting, cytochrome c
oxidase, and NADH dehydrogenase subunits in male PD. For
the ubiquitin proteasome system we also observed a mixed
picture of up- and downregulated gene groups in both genders.
Noticeable differences could be seen for heatshock and ubiquitin-
associated proteins that were more downregulated in either mPD
or fPD, respectively. Interestingly, in both groups, there was a
prominent upregulation of Zink finger proteins, although without
a clear overlapping pattern between the genders. Differences of
gene expression related to synaptic function and cytoskeleton
could be observed for all gene groups between both genders.
Consistent with our previous report [12], there was an overall
upregulation of genes related to cell survival but without obvious
difference between mPD and fPD. In the stringent conditions
we found a more prominent downregulation of GABA recep-
tor subunits and associated proteins in mPD, while in both
genders gene groups for glutamate, cholinergic, somatostatin and
dopaminergic receptors were upregulated. For the ion-channel
related transcripts, there was a mixed picture of up- and down-
regulated genes in both groups without a clear bias to either
gender.
Figure 3. Gene-Term Association Network (GTAN) of selected GO-BP terms (oxidative phosphorylation, apoptosis, synaptic
transmission, transmission of nerve impulse) in a population of genes that are deregulated in both allN_allPD SAM and allN_allPD
3-Way ANOVA groups, as well as mPD based on FDR5 p,0.01 analysis. Shown are paramount PD-related transcripts that overlap between
the terms.
doi:10.1371/journal.pone.0008856.g003
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Our computational data set indicated that deregulated gene
expression in PD is gender-specific with a bias of some key genes
towards the male gender. To further corroborate this finding, we
composed a list of genes that fulfilled the following criteria: 1.
Enrichment in pathway-level comparative analysis (see above); 2.
Association with PD pathogenesis; 3. Other previously published
microarray studies on PD (summarized in [15], https://ncascr.
griffith.edu.au/pdreview/2008/); and 4. Overlap with genetic
association studies on PD phenotypes (www.pdgene.org) and data
from four main PD Genome-Wide Association Studies (GWAS)
[17,18,19,20,21]. In both the stringent and relaxed data analysis,
this list of 36 key genes (Table 4) contained 15 probesets that were
deregulated in mPD, 10 in fPD and only 2 that overlapped
between both genders, while 9 probesets changed when the
p-values were shifted from ,0.01 to ,0.05. This result is largely
consistent with the data from the pathway-enrichment and gene
cluster analyses indicating a gender-specific dysregulation of gene
expression in PD-affected DA neurons with a possible bias towards
the male gender.
Validation of Microarray Data Using TaqManH-Based
Real-Time PCR
Finally, we validated some of the microarray results using
TaqManH-based qRT-PCR on laser-microdissected neurons
according to our previous study [12]. For data consistency and
because of the differences in PARK gene expression (see above),
we used the same qRT-PCR array amplifying the gene products
for tyrosine hydroxylase (TH), dopamine transporter (DAT or
SNC6A3), Girk2 (KCNJ6) and all PARK genes (Table 3)
including LRKK2, which was not present on the HG-U133A
Affymetrix chip. In the male groups, three additional samples were
added for controls and PD, respectively. In the female group we
included two control and three PD samples. Data were analyzed
according to the 2
2DCt method [16] using GUSB as internal
control for normalization. These experiments largely confirmed
Figure 4. Gender-specific expression profiles of probesets relevant to pathways in PD based on FDR5 p,0.01 analysis. Heatmaps
showing up- or downregulated genes in female (mN_fPD) and male (mN_mPD) PD compared to all other groups. In all pathways, the overwhelming
number of genes was dysregulated in either gender with little overlap between both groups. Note: allN_allPD A3W depicts probesets from the
ANOVA FDR10 gene list previously published [12].
doi:10.1371/journal.pone.0008856.g004
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expression of individual genes (up to 2 logs and regardless of
disease or gender) and across the sample population (Figure 5). In
addition, there was overall lower gene expression in the PD
samples and, to our surprise, also for most of the PARK genes. To
corroborate these findings, we additionally plotted the results as
heat maps and scatter plots (Figure S7). On the individual sample
level, there was high consistency between the normalized values in
z-scores and the 2
2DCt values and a general down-regulation of
gene expression in the PD samples (Figure S7a-e). It should be
noted that in the male PD population two probesets for SNCA
showed up- and two probesets down-regulation in the z-scores
(Figure S7a and d). Also, in both female and male PD, the z-scores
for Parkin were upregulated (Figure S7a and e), although this
result seemed to be exaggerated, since the difference from the
mean expression level was very small (Figure S7b). Finally, we
compared the qRT-PCR results with the data points from the
SAM analyses. After data transformation, we found that there was
higher correlation with the values derived from the relaxed (FDR5
p,0.05) than with the stringent criteria (FDR5 p,0.01) (Table 3).
Discussion
Our study demonstrates that deregulated gene expression in PD
follows different patterns between genders with indication of a male
bias towards the disease. These results are somewhat in line with
studiesonpatient populationsconcluding thatthe malegendercould
represent a risk factor for the development of sporadic PD [2,3,4,5]
and could also support clinical observations on gender-specific
disease development and progression [6,7]. Based on a multi-leveled
approach using PD-relevant pathway analysis [12], computational
and gene-term association networks as well as comparative data
mining from published literature on PD pathogenesis, gender effects,
and PD-associated gene lists, we identified a set of genes that we
suggest as primary factors in PD and gender specificity.
Gender-Specific Expression Profiles in Aged Control DA
Neurons and Their Implication on PD
Epidemiological studies suggested that gender- and race-related
genetic factors could influence the function of DA neurons and,
consequently, the risk for PD. In control age-matched DA
neurons, we observed 106 transcripts that were differentially
expressed between females and males with 92 of them higher
expressed in males. Many of these genes were involved in multiple
aspects of cellular homeostasis and also included some key
molecules in energy-consuming mitochondrial processes, such
GSTT1, KCNN3, NDUFC1, S100A1, and SLC11A2 suggesting
a male-specific increase in mitochondrial activity and Ca
2+
homeostasis. Since these and several other upregulated transcripts,
such as APBA2, DNAJC7, DNM2, MAPT, ST13 and TNS1 are
linked to PD pathogenesis, our data could support previous
suggestions that a high metabolic rate of DA neurons might
accelerate their ageing and predisposition to PD [22]. Thus, this
conclusion would imply that levels of gene expression are not only
a characteristic of disease state, but could also be a factor in disease
development. Indeed, our qPCR analysis demonstrated that gene
expression differs across normal control subjects and that
expression levels of different genes substantially vary (.2 logs)
within the same LMD DA neuron pool. It appears therefore that a
combination of gene expression levels, individual predisposition
(e.g. genetic variability [23]), and gender could influence the
vulnerability or protection of DA neurons towards the develop-
ment of PD.
Gene Expression Profiles in Late-Stage PD DA Neurons
In our study the overwhelming number of deregulated genes did
not overlap between females and males. In fact, only 3.7% or 18%
of the deregulated transcripts were up- or downregulated in both
genders using the stringent (p,0.01) or relaxed (p,0.05) analysis
criteria, respectively. This group included transcripts relevant to
PD cellular pathways, such as mitochondrial function, synaptic
transmission, neurotransmitter and ion channel activity, and
therefore, could represent a set of disease-driving genes that are
common to both male and female PD (e.g. CHRNA4, CLTC,
COX7C, DRD2 and NDUFB2). However, regardless of these
common transcripts, the high divergence between the genders
indicated that the expression profiles of PD-affected DA neurons
seem to be gender-specific. This was also evident when we
clustered the data according to the established signaling pathways
linked to PD [12]. Interestingly, this analysis did not demonstrate
Table 3. Genes associated with PD linkage (PARK loci).
PARK
Gene
Symbol
GenBank
ID Description All
1
Males
p,0.01
Males
p,0.05
Females
p,0.01
Females
p,0.05
PARK1 SNCA BG260394 synuclein alpha 21.97 22.12 21.13 21.8
PARK2 Parkin NM_004562 PD (autosomal recessive, juvenile) 2
PARK5 UCH-L1 NM_004181 ubiquitin carboxyl-terminal esterase L1 21.88 21.72
HIP2 NM_005339 huntingtin interacting protein 2 21.21 1.20
2 1.2
PARK6 PINK1 AF316873 PTEN induced putative kinase 1 22.06 21.83 21.83 22.56
PARK7 DJ-1 NM_007262 PD (autosomal recessive early onset) 7 27.08 29.09 28.37
PARK9 ATP13A2 NM_022089 ATPase type 13A2 21.34 21.64
PARK10 RAP1GAP AB007943 RAP1 GTPase activating protein 1.40 1.36 1.36 1.47
RIMS1 AF263310 reg. synaptic membrane exocytosis 1 1.20
RIMS3 NM_014747 reg. synaptic membrane exocytosis 3 22.51 25.47 25.47
PARK13 HTRA2 mitochondrial serine protease 21.54
3 21.33
1data combined for p,0.01 and p,0.05.
2HIP1 (U79734).
3HTRA1 (NM_002775).
doi:10.1371/journal.pone.0008856.t003
Gender and Transcriptome in PD
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8856an obvious PD-linked biological divergence between both groups,
i.e., neither profile pointed to a particular or prominent gender-
specific dysfunction of PD-relevant pathways. Rather, there was a
marked divergence amongst subtypes of single gene families,
which could have been the driving force in the pathway
enrichments resulting in the observed male bias towards PD.
A gene group of special interest refers to the PARK genes,
which have been linked to familial forms of PD [24,25] and our
previous data analysis [12] together with results from other studies
[26,27,28,29] have provided evidence that these molecules are also
involved in idiopathic PD. Our results from the gender analysis
revealed that SNCA, DJ-1 and PINK1 were exclusively down-
regulated in male PD under the stringent (FDR5, p,0.01) analysis
criteria. However, both the relaxed conditions (FDR5, p,0.05)
and the qRT-PCR experiments showed a general trend towards
similar down-regulation of all PARK genes in both genders,
Table 4. Key genes associated with PD.
Gene Symbol GenBank ID Description
All
1
p,0.01
Males
p,0.01
Males
p,0.05
Females
p,0.01
Females
p,0.05
Genes associated with PCD and mitochondrial function
TNFRSF1A NM_001065 tumor necrosis factor receptor 1A 0001 . 2 5 1 . 2 6
PINK1 NM_032409 PTEN induced putative kinase 1 22.08 21.85 21.82 0 22.55
SOD1 NM_000454 superoxide dismutase 1, soluble 23.44 23.44 23.44 0 0
PARK7 NM_007262 Parkinson disease 7 27.14 29.09 28.37 0 0
NDUFA6 NM_002490 NADH dehydrogenase 6, 14 kDa 21.80 0 22.19 21.56 22.07
NDUFB8 NM_005004 NADH dehydrogenase 8, 19 kDa 27.14 25.55 23.00 0 210.96
CYP1A1 NM_000499 cytochrome P450, family 1, subfamily A 1.2 0 0 1.36 1.36
CYP2C9 NM_000771 cytochrome P450, family 2,subfamily C 0 1.23 1.23 0 0
APAF1 NM_181869 apoptotic peptidase activating 1 1.35 1.41 1.40 0 0
GSTA4 NM_001512 glutathione S-transferase A4 21.38 21.38 21.38 0 0
Genes associated with protein degradation
SNCA NM_007308 synuclein, alpha 21.88 22.12 21.12 0 21.84
PSMA7 NM_002792 proteasome alpha, 7 21.72 0 0 21.78 21.77
HSP90AA1 NM_005348 heat shock protein 90 kDa alpha 22.70 23.33 23.46 0 0
HSPA8 NM_153201 heat shock 70 kDa protein 8 22.77 23.70 21.35 0 0
LAMP1 NM_005561 lysosomal-associated membrane protein 1 0 0 0 212.50 211.50
PPARD NM_006238 peroxisome proliferator-activated receptor d 0 1.20 1.20 0 0
Growth factors, receptors and ion channels
DRD1 NM_000794 dopamine receptor D1 0001 . 3 7 1 . 3 7
DRD2 NM_016574 dopamine receptor D2 1.26 1.32 1.32 1.32 1.32
CHRNA4 NM_000744 cholinergic receptor, nicotinic,alpha 4 1.25 1.22 1.22 1.4 1.40
GABARAPL2 NM_007285 GABA(A) receptor-associated protein-like 2 21.53 21.51 21.50 0 21.54
GRIN2B NM_000834 glutamate receptor, NMDA 2B 1.27 1.27 1.27 0 1.25
TGFB2 NM_003238 transforming growth factor, beta 2 1.24 0 1.24 1.33 1.33
KCNN3 NM_170782 potassium intermediate/small conductance
Ca-activating channel, subfamily N, member 3
00021.92 21.91
SLC24A3 NM_020689 solute carrier family 24 (Na/K/Ca exchanger) 0 21.56 21.55 0 0
SLC6A4 NM_001045 solute carrier family 6 (serotonin) 0001 . 3 3 1 . 3 3
CCK NM_000729 cholecystokinin 21.23 21.31 21.30 0 0
CCKAR NM_000730 cholecystokinin A receptor 1.31 1.31 1.31 0 0
VDR NM_001017535 vitamin D receptor 1.39 1.39 1.39 0 1.31
FYN NM_153048 FYN oncogene related to SRC, FGR, YES 21.19 21.19 21.19 0 21.92
RIPK2 NM_003821 receptor-interacting serine-threonine kinase 2 1.29 0 0 1.29 1.29
Other
MAPT NM_016841 microtubule-associated protein tau 250 0 25 24.9
FTH1 NM_002032 ferritin, heavy polypeptide 1 22.81 22.77 22.74 0 0
FTL NM_000146 ferritin, light polypeptide 21.88 21.81 21.80 0 0
PPP1R3A NM_002711 protein phosphatase 1, regulatory (inhibitor) 3A 1.25 1.24 1.24 0 0
PPP3CA NM_000944 protein phosphatase 3 alpha 22.56 23.03 22.94 0 0
ST13 NM_003932 supp. of tumorigenicity 13 (Hsp70 inter. prot.) 21.67 0 0 21.64 21.67
doi:10.1371/journal.pone.0008856.t004
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sets could be due to multiple factors. For example, all PARK genes
except of UCHL1 were relatively low expressing genes raising the
question of how significant differential gene expression profiles in
microarray studies are. It is common that low expressing genes in
microarrays are usually difficult to validate and can often be
filtered out from the analysis. Here, we did not filter these terms
due to their claimed importance in PD pathogenesis. In addition,
in male PD two probes for SNCA revealed up- and two probes
downregulation by z-scores pointing to an even more complex
level of assessing gene expression that relates to the detection of
different splice forms. Nevertheless, our extended qPCR analysis
together with the microarrays demonstrated a more general down-
regulation of PARK in PD. This has implication for disease
pathogenesis, since the PARK proteins influence several key
pathways of cellular function including oxidative phosphorylation,
apoptosis, synaptic transmission, and transmission of nerve
impulse, all pathways that seem to be more affected in male PD.
We eventually evaluated the gene expression profiles combining
differentcriteria,such asPD-relevantpathwayanalysisaspreviously
described [12], computational gene-term association networking,
and comparative data mining from published literature on PD
pathogenesis and PD-associated gene lists. These analyses in
association with gender-specificity identified a set of genes that
could be primary factors in PD and could be involved in a
predisposition of males towards this disorder (Table 4). A prominent
group of deregulated genes referred to PCD and mitochondrial
dysfunction, such as DJ-1 (PARK7), which serves as a redox-
sensitive chaperone in oxidative stress response [30]. Its mutation
causes recessive early-onset PD [31]. Recently, it has been shown
that DJ-1 forms a ubiquitin E3 ligase complex together with Parkin
and the serine-threonin mitochondrial kinase PINK1 and promotes
the degradation of miss-folded proteins [32]. DJ-1 and PINK1 were
downregulated in both genders with a trend towards the male
population. Interestingly, there seems to be a connection between
PINK1 and the TNF pathway, as one of PINK1’s substrates is the
TNF-receptor associated protein 1 (TRAP1) [33], which was
downregulated in male PD. In addition, there was deregulation of
several other genes linked to TNF pathways specific to both males
and females and from the group of primary factors, we found a
1.25-fold upregulation of the TNF receptor 1A in the female
population. These data indicate that molecules related to extrinsic
apoptosis might also contribute to gender-specificity in PD
pathogenesis. Another markedly downregulated ‘‘male-specific’’
gene related to oxidative stress response was SOD1, which is
primarily associated with amyotrophic lateral sclerosis (ALS), but
common pathways with PD have been suggested [34]. A reduction
in its activity has been reported as a commonality between PD,
Alzheimer’s disease, ALS and Huntington’s disease [35]. The list of
genes also included several members of the mitochondrial electron
transport chain like complex I-associated NADH dehydro-
genase, cytochrome P450, and glutathione S-transferase family
members, which are potentially important in PD pathogenesis
[36,37,38,39,40]. These genes are deregulated in both genders with
a trend towards a male bias. PCD is also associated with disruption
of the UPS and mechanisms of protein degradation [41]. From the
key genes related to this PD-associated pathway, the heat shock
family members HSP90AA1 and HSPA8 are downregulated in
males, while the proteasome alpha subunit 7 (PSMA7) is
downregulated in females, which could indicate a ‘‘stronger’’
impact of the disease on disrupting metabolic processes in the male
population. Interestingly, females exhibited markeddownregulation
Figure 5. Validation of gene expression by TaqManH qRT-PCR. Data were analyzed using the 2
2DCt method [16] and plotted as relative
expression levels of individual genes when normalized to GUSB as internal controls. The bars depict results from six individual male (C1, C2, C3, C4,
C10, C11) and two female controls (C8, C9) as well as six male PD (PD1, PD3, PD4, PD6, PD11, PD14) and three female PD samples (PD8, PD10, PD13)
(Table S1). Note that samples C3, C10, C11, PD3, PD4, and PD11 were taken from [12]. Genes were clustered according to high (DAT, UCHL1), medium
(Girk2, SNCA, HIP2, DJ-1, ATP13A2, RAP1GA1), and low (TH, Parkin, PINK1, LRRK2, RIMS1 and 3) expressing genes.
doi:10.1371/journal.pone.0008856.g005
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associated with the function of phagosomes, endosomes and
lysosomes. For example, this molecule has been linked to impaired
endosome and phagosome movement by disrupting dyneins [42,43]
implicating its association with molecules of the cytoskeleton and its
potential role in disrupting cytoskeletal cell function in PD.
It is commonly established that the dynamics of growth factor
function, neurotransmitter receptor and ion channel activity in
nigral dopaminergic neurons are an important aspect of PD
pathogenesis [22,44,45,46,47,48]. In agreement with our previous
study, the list of PD-associated primary factors contains several of
them that are dysregulated in both females and males, but
predominance in the male population was less evident. In
particular, we observed an upregulation of the dopamine receptors
1 and 2, cholinergic receptor alpha 4, glutamate receptor 2, and
transforming growth factor beta 2, while the transcript for
GABA(A) receptor associated protein was downregulated. An
interesting observation was the upregulation of the vitamin D
receptor (VDR) and downregulation of ferritin light polypeptide
(FTL) and ferritin heavy polypeptide 1 (FTH1) with some bias
towards the male population. Vitamin D deficiency has been
linked to an increased incidence of PD [49] and there is evidence
that iron metabolism is associated with PD pathogenesis
[50,51,52,53]. Another set of genes relevant to PD pathogenesis
is cholecystokinin (CCK) and its receptors (CCKAR), which are
down- and upregulated in males, respectively. Cholecystokinin is
involved in modulating dopamine in the mesolimbic pathway and
implicated in the psychiatric symptomatology of PD. A recent
gene-linkage study supports the notion that CCK and CCKR
polymorphism might be associated with hallucinations in PD [54].
Finally, the list of genes contains suppression of tumorigenicity 13
(ST13) and microtubule-associated protein tau (MAPT). ST13 is
part of a number of marker genes that were recently proposed as
possible biomarkers in PD [55] and MAPT is linked to neurologic
disorders associated with dementia syndromes, such as Alzhei-
mer’s disease, Pick’s disease, frontotemporal dementia, agryophil-
lic grain disease, and progressive supranuclear palsy [56]. A recent
genome-wide association study identified this gene as a risk factor
for the development of familial PD [19]. Interestingly, ST13 and
MAPT are downregulated in the female PD population indicating
that these genes might also be implicated in a gender-specific
development and progression of PD.
Gene Expression Profiling in Postmortem Laser-Isolated
Neurons
The interpretation of data from gene expression profiles based
on microarrays or qRT-PCR on laser-isolated neurons from
postmortem brain material bears several caveats. These include
quality of postmortem brain tissue, sample preparation, method-
ology of laser-capture, quality of isolated and processed RNA,
choice of microarray chip, probe design (e.g. detection of splice
forms), array methodology, choice of primers, internal controls
and method of quantitative Real-Time PCR, methodology of
computational analysis including choice of algorithm, batch
effects, cut-offs, replicates, and significance. Altogether, the
complex interplay of these parameters represents a ‘‘dynamic’’
system in data generation and interpretation.
Restricted sample size is one of common problems in microarray
studies of difficult-to-obtain sample populations, such as female
sporadic PD in our study. Pathway enrichment can be used to
compensate for this restriction, obtaining insightful information on
the overall biological themes and overcoming common variations
and fluctuations at the gene-level, which are embedded in data
derived from either natural genetic variations or high-throughput
experiments [14,57]. We used two relevant methods that emphasize
pathway-level enrichment patterns and consistency: Pathway
pattern extraction pipeline (PPEP) and Sample-Level Enrichment-
Based Pathway Ranking (SLEPR) [14,57]. Both methods promote
pathway-level comparative analysis of multiple gene lists or datasets
on top of commonly used pathway enrichment analysis of a single
gene list. Especially PPEP has been applied to a wide variety of
different data sets, such as microarray data, mass spectrometry data,
and data of genetic screening to uncover biological themes
[58,59,60,61,62,63,64,65,66]. In our study, these analyses robusti-
cally revealed a male bias for signaling pathways relevant to PD
pathogenesis,whichotherwise would have been embedded amongst
the variations at the gene-level, and demonstrated strong pathway
enrichment in mPD using both stringent and relaxed analysis
criteria, while females showed some enrichment at low levels only in
the relaxed conditions. However, we also noticed that a gender
effect was lost for some individual genes, such as PARK, when the
relaxed criteria were applied - also attesting to the power of
pathway-level comparative analysis. This demonstrated that the
choice of cut-offs influenced gender-specificity on the single gene
level that may be sensitive to genetic variations of individuals even
from the same class (i.e. PD or normal control), but did not alter the
overall outcome of the data set at large, which was retrieved by
pathway-level comparative analysis. It should be noted that many of
the excluded genes in the stringent criteria were ‘‘borderline cases’’
due to the narrow margin of significance applied by the cut-off shift
from p,0.01 to p,0.05. Also, in case of genes, for which multiple
probes were present, the two different stringencies selected different
probes, from which the average values were calculated. For
example, in mPD only two out of four probes for SNCA passed
the p,0.05 cut-off, one being 2.1 fold down- and the other 1.3 fold
up-regulated revealing a value of -1.13, further demonstrating the
influence of multiple factors in data generation and gene-level
assessment.
Conventional microarray analyses have contributed to the
mechanistic understanding of complex disorders by attempting to
determine conserved individual gene level changes. Pathway
analysis has emerged as an alternative or compensation for
conventional gene analysis, because it can cover both conserved
and not conserved changes within small sample populations and
can uncover changes that otherwise would have been overlooked
by conventional methods. For example, conserved gene level
changes may only exist in a subset of a sample population
characterized by parameters such as race, aging, and others, but
not in the variable of interest (i.e. gender in our analysis). Focusing
on the ‘‘well behaved’’ or conserved gene changes alone would not
only impede the choice of sample collection, but would also make
conclusions and findings more subjective by selecting only those
parameters that define the subsets of a population containing these
conserved changes. In addition, it is common that relevant
changes within certain phenotypes (in our study the differences in
PD pathogenesis between genders) could occur for different genes
in a relevant pathway across the individuals of a study population.
Even for the same gene, changes could occur at different
expression levels or aspects of function within different individuals,
i.e., at the level of transcription, translation, or post-transla-
tional modification. Microarrays are just measuring one aspect
of these many possible aspects. Since conserved gene-level
changes are rather rare events, differ between individuals, and
methodologically difficult to assess, pathway-level analysis detects
multiple relevant gene changes in different individuals within
the same phenotype (here, PD), which consists of the entire
repertoire of all responsible changes eventually leading to the same
phenotype: PD.
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not based on single genes, but are rather a consequence of
complex networks of signaling pathways that are driven by
multiple gene functions. This is also true for disease processes and
in particular in complex diseases, such as cancer, heart diseases,
hypertension, and sporadic neurodegeneration, which have been
associated with polymorphisms of multiple genes in the same or
related pathway or caused by a single but different gene within
individuals leading to biological changes in the same or related
pathway among a given population. Pathway analysis offers the
opportunity to deal with a group of relevant genes in such
pathways instead of focusing on individual (conserved) gene level
changes and, thus, could better reflect biological processes
[58,59,60,61,62,63,64,65,66]. In this sense, data from pathway
analysis could have implication on future aspects of understanding
disease processes and could help to develop methodologies for
assessing the outcome of pathway damage from sample to sample
eventually determining which set of genes could be candidate
targets to be screened and identified for diagnosis, treatment and
even disease prevention.
Data validation using qRT-PCR demonstrated an overall good
correlation ofarrayrawdata(normalized valuesinz-scores)withthe
qRT-PCR results (2
2DCt method [16]) across all samples. However,
despite this data confirmation, the validation on a small number of
genes and samples was less evident when compared with the array
data after analysis with SAM. Although there was a trend for some
genes towards stronger down-regulation in males, overall the PCR
revealed similar reduction of gene expression between control and
PD samples for both genders. Interestingly, these results correlated
better with the relaxed p,0.05 criteria and, therefore, point to
a general caveat in computational data analysis of determining
appropriate cut-offs. Despite the results from the pathway enrich-
ment analysis, the validation of potentially conserved individual
gene level changes by qRT-PCR would require further studies on
additional biological replicates including a larger amount of female
subjects. Finally, the PCR experiments also confirmed our previous
observation that gene expression levels substantially varied between
individual genes as well as subjects and some of the genes, such as
TH, Parkin, LRKK2, RIMS1 and 3 were very low expressed. This
could be an important parameter to putinto perspectivesomeof the
array results and especially for those genes that areexpressed at very
low levels.
We attempted to re-analyze the microarray data published by
Cantuti-Castelvetri et al. [11] according to our criteria. These
investigators also analyzed the gene expression profiles of laser
captured DA neurons from female and male normal subjects and
sporadic PD patients and reported dissimilarity of gene deregu-
lation patterns in signal transduction, neuronal maturation,
protein kinases, proteolysis and the WNT signaling pathway with
a predisposition of males to PD. Unfortunately, using our stringent
and relaxed analysis conditions we were not able to retrieve a
comprehensive data set that allowed for a comparative analysis
with our results: For example, the group of mN_fN contained 305
genes with 301 upregulated probesets. In female PD (fN_fPD) only
5 probesets were present in both the p,0.01 and p,0.05
conditions, while in mPD (mN_mPD) 175 probesets were found
with p-values ,0.01 (172 were down-regulated) and 1241 with
p,0.05. When we looked at the deregulated genes in these groups,
the majority was not relevant to PD signaling pathways. These
discrepancies could have been due to some substantial differences
between both studies: 1.) As already discussed previously [12],
Cantuti-Castelvetri et al. used laser-capture microscopy (LCM)
with an Arcturus PixCell II instrument and a different sample
preparation protocol based on quick immunostaining or ethanol
fixation and methylene blue staining. In addition, this study was
based on the Affymetrix U133_X3P platform, which consists of a
different set of probesets than the HG-U133A chip used in our
study. 2.) Our computational analysis takes in account two
important parameters for data transformation: Batch effect and
Principal Component Analysis (PCA). Consistent with our
ANOVA analysis [12], PCA plots of data after removal of a
batch effect by an ANOVA model showed a clear pattern formed
by the PD versus normal samples. This, however, was not the case
for the data by Cantuti-Castelvetri et al. and indicated profound
differences in the sets of microarray samples between both studies.
It should be noted that, on the single gene level, dissimilarities
between the two microarrays could also be observed in an
independent computational analysis publicized on the National
Center for Adult Stem Cell Research (NCASCR) - Parkinson’s
Disease Review Database (https://ncascr.griffith.edu.au/pdreview/
2009/).
Taken together, our data provide insight into some of the
molecular events of sporadic PD and a potential role of gender in
disease pathogenesis. The results could support the notion that the
male gender is a risk factor for PD and could indicate a profound
impact of gender on the function of normal and PD-affected DA
neurons. Moreover, they imply that a relatively small set of
primary factors could represent key molecules that drive disease
mechanisms and gender-specificity. Altogether, we believe that our
data provide a platform for future investigations on understanding
the role of gender in PD pathogenesis.
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Table S1 Statistics of cases used for LMD and RNA
information.
Found at: doi:10.1371/journal.pone.0008856.s001 (0.11 MB
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Figure S1 Heatmaps based on FDR5 p,0.01 of all 6 gene lists
(Table S2) merged by BaseGenBankID of WPS. In case of
multiple probes for the same gene, data are plotted as the average
of fold change for each gene.
Found at: doi:10.1371/journal.pone.0008856.s006 (0.04 MB PPT)
Figure S2 Distribution of gene expression profiles for all groups
based on FDR5 p,0.05 analysis as shown in Figure 1. The groups
are as follows: allN_allPD compares all normal versus all PD
samples; mN_fN compares control males versus control females;
mN_mPD compares control males versus male PD; fN_fPD
compares control females versus female PD; the overlapping
groups indicate the number of genes that are found in several
respective groups. Bars represent numbers of up- or downregu-
lated genes in each group for total genes or after setting the cut-off
of differential gene expression at .1.5 fold.
Found at: doi:10.1371/journal.pone.0008856.s007 (0.18 MB PPT)
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based on FDR5 p,0.01 using BioCarta (A) and KEGG (B) for
all gene lists (Table S2). There was more enrichment of probesets
in pathways relevant to PD pathogenesis in the mPD gene list
(mN_mPD).
Found at: doi:10.1371/journal.pone.0008856.s008 (0.09 MB PPT)
Figure S4 Comparative pathway-enrichment level analysis
based on FDR5 p,0.01 using GO-BP for all lists (A), allN_allPD
with mN_mPD (B), and allN_allPD with fN_fPD (C) (Table S2).
There was prominent enrichment of probesets in pathways
relevant to PD pathogenesis in mPD. Note that allN_allPD
A3W depicts probesets from the ANOVA FDR10 gene list
previously published [12].
Found at: doi:10.1371/journal.pone.0008856.s009 (0.24 MB PPT)
Figure S5 Comparative pathway-enrichment level analysis
based on FDR5 p,0.01 using GSEA function annotation for all
lists (A), allN_allPD with mN_mPD (B), and allN_allPD with
fN_fPD (C) (Table S2). There was prominent enrichment of
probesets in pathways relevant to PD pathogenesis in mPD. Note
that allN_allPD A3W depicts probesets from the ANOVA FDR10
gene list previously published [12].
Found at: doi:10.1371/journal.pone.0008856.s010 (0.30 MB PPT)
Figure S6 Comparative pathway-enrichment level analysis
based on FDR5 p,0.01 and p,0.05 for all gene lists. (A) The
complete list of terms for GO-BP and GSEA showed more
consistent enrichment for allN_allPD and mN_mPD than for
fN_fPD. (B–D) Selected lists for GO-BP (B), GSEA (C) and
KEGG (D) analysis demonstrated stronger and more prominent
enrichment of terms (arrows) related to oxidative phosphorylation,
synaptic transmission and transmission of nerve impulse in mPD
than in fPD, but to lesser extend for apoptosis.
Found at: doi:10.1371/journal.pone.0008856.s011 (1.16 MB PPT)
Figure S7 Comparison of gene expression levels in the
microarrays before data transformation (normalized values in z-
scores) with data from the qRT-PCR assays. (A–B) Heat maps of
z-scores for the 14 genes analyzed in all individual samples after
removal of batch effects (Material and Methods and [12]). The
heatmaps in (B) depict the differences from mean levels. (C–E)
Scatter plots summarizing the values for the z-scores in
comparison with the values of relative gene expression (2
2DCt)
from the qRT-PCR results. Black dots represent control and red
dots PD samples. Note, that genes were clustered according to
high (DAT, UCHL1), medium (Girk2, SNCA, HIP2, DJ-1,
ATP13A2, RAP1GA1), and low (TH, Parkin, PINK1, LRRK2,
RIMS1 and 3) expressing genes.
Found at: doi:10.1371/journal.pone.0008856.s012 (0.37 MB PPT)
Author Contributions
Conceived and designed the experiments: FS MY YW RS KCS.
Performed the experiments: FS MY YW RS KCS. Analyzed the data:
FS MY YW RS KCS. Contributed reagents/materials/analysis tools: FS
MY YW RS KCS. Wrote the paper: FS MY RS KCS.
References
1. Braak H, Del Tredici K (2008) Invited Article: Nervous system pathology in
sporadic Parkinson disease. Neurology 70: 1916–1925.
2. Taylor KS, Cook JA, Counsell CE (2007) Heterogeneity in male to female risk
for Parkinson’s disease. J Neurol Neurosurg Psychiatry 78: 905–906.
3. Twelves D, Perkins KS, Counsell C (2003) Systematic review of incidence
studies of Parkinson’s disease. Mov Disord 18: 19–31.
4. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J (2004) Are men at greater
risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75:
637–639.
5. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, et al.
(2003) Incidence of Parkinson’s disease: variation by age, gender, and race/
ethnicity. Am J Epidemiol 157: 1015–1022.
6. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, et al. (2007)
Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:
819–824.
7. Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, et al. (2006)
Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor
fluctuations. Mov Disord 21: 1384–1395.
8. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC (1998) Gender
differences in Parkinson’s disease. Clin Neuropharmacol 21: 118–121.
9. Uitti RJ, Baba Y, Wszolek ZK, Putzke DJ (2005) Defining the Parkinson’s
disease phenotype: initial symptoms and baseline characteristics in a clinical
cohort. Parkinsonism Relat Disord 11: 139–145.
10. Burn DJ (2007) Sex and Parkinson’s disease: a world of difference? J Neurol
Neurosurg Psychiatry 78: 787.
11. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, Asteris G, Clark TW, et al.
(2007) Effects of gender on nigral gene expression and parkinson disease.
Neurobiol Dis 26: 606–614.
12. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, et al. (2009) Gene expression
profiling of substantia nigra dopamine neurons: further insights into Parkinson’s
disease pathology. Brain 132: 1795–1809.
13. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, et al. (2007)
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and
bipolars. Proc Natl Acad Sci U S A 104: 10164–10169.
14. Yi M, Mudunuri U, Che A, Stephens RM (2009) Seeking unique and common
biological themes in multiple gene lists or datasets: pathway pattern extraction
pipeline for pathway-level comparative analysis. BMC Bioinformatics 10: 200.
15. Sutherland GT, Matigian NA, Chalk AM, Anderson MJ, Silburn PA, et al.
(2009) A cross-study transcriptional analysis of Parkinson’s disease. PLoS ONE
4: e4955.
16. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
17. Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, et al. (2006)
Genome-wide genotyping in Parkinson’s disease and neurologically normal
controls: first stage analysis and public release of data. Lancet Neurol 5:
911–916.
18. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, et al.
(2005) High-resolution whole-genome association study of Parkinson disease.
Am J Hum Genet 77: 685–693.
19. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. (2009)
Genomewide association study for susceptibility genes contributing to familial
Parkinson disease. Hum Genet 124: 593–605.
20. Simon HH, Saueressig H, Wurst W, Goulding MD, O’Leary DD (2001) Fate of
midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci
21: 3126–3134.
21. Srinivasan BS, Doostzadeh J, Absalan F, Mohandessi S, Jalili R, et al. (2009)
Whole genome survey of coding SNPs reveals a reproducible pathway
determinant of Parkinson disease. Hum Mutat 30: 228–238.
22. Surmeier DJ (2007) Calcium, ageing, and neuronal vulnerability in Parkinson’s
disease. Lancet Neurol 6: 933–938.
23. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, et al. (2007) A survey of
genetic human cortical gene expression. Nat Genet 39: 1494–1499.
24. Cookson MR (2005) The biochemistry of Parkinson’s disease. Annu Rev
Biochem 74: 29–52.
25. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophys-
iology of Parkinson’s disease. Annu Rev Neurosci 28: 57–87.
26. Burke RE (2008) Programmed cell death and new discoveries in the genetics of
parkinsonism. J Neurochem 104: 875–890.
27. Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, et al. (2007)
Analysis of alpha-synuclein, dopamine and parkin pathways in neuropatholog-
ically confirmed parkinsonian nigra. Acta Neuropathol 113: 253–263.
28. Schiesling C, Kieper N, Seidel K, Kruger R (2008) Review: Familial Parkinson’s
disease–genetics, clinical phenotype and neuropathology in relation to the
common sporadic form of the disease. Neuropathol Appl Neurobiol 34:
255–271.
29. Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16 Spec No. 2:
R183–194.
30. Kahle PJ, Waak J, Gasser T (2009) DJ-1 and prevention of oxidative stress in
Parkinson’s disease and other age-related disorders. Free Radic Biol Med 47:
1354–1361.
31. Yang YX, Wood NW, Latchman DS (2009) Molecular basis of Parkinson’s
disease. Neuroreport 20: 150–156.
32. Xiong H, Wang D, Chen L, Choo YS, Ma H, et al. (2009) Parkin, PINK1, and
DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein
degradation. J Clin Invest 119: 650–660.
33. Pridgeon JW, Olzmann JA, Chin LS, Li L (2007) PINK1 Protects against
Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1. PLoS
Biol 5: e172.
Gender and Transcriptome in PD
PLoS ONE | www.plosone.org 13 January 2010 | Volume 5 | Issue 1 | e885634. Martin LJ, Liu Z, Chen K, Price AC, Pan Y, et al. (2007) Motor neuron
degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1
transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp
Neurol 500: 20–46.
35. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C (2008) Free copper,
ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the
CSF. A different marker profile in four neurodegenerative diseases. Neurochem
Res 33: 1717–1723.
36. Mellick GD (2006) CYP450, genetics and Parkinson’s disease: gene x
environment interactions hold the key. J Neural Transm Suppl: 159–165.
37. Miksys S, Tyndale RF (2006) Nicotine induces brain CYP enzymes: relevance to
Parkinson’s disease. J Neural Transm Suppl: 177–180.
38. Patel S, Singh V, Kumar A, Gupta YK, Singh MP (2006) Status of antioxidant
defense system and expression of toxicant responsive genes in striatum of maneb-
and paraquat-induced Parkinson’s disease phenotype in mouse: mechanism of
neurodegeneration. Brain Res 1081: 9–18.
39. Viaggi C, Pardini C, Vaglini F, Corsini GU (2006) Cytochrome P450 and
Parkinson’s disease: protective role of neuronal CYP 2E1 from MPTP toxicity.
J Neural Transm Suppl: 173–176.
40. Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity
and neurological disorders. Neuron 60: 748–766.
41. Tan JM, Wong ES, Lim KL (2009) Protein misfolding and aggregation in
Parkinson’s disease. Antioxid Redox Signal 11: 2119–2134.
42. Cai ZL, Shi JJ, Yang YP, Cao BY, Wang F, et al. (2009) MPP+ impairs
autophagic clearance of alpha-synuclein by impairing the activity of dynein.
Neuroreport 20: 569–573.
43. Loubery S, Wilhelm C, Hurbain I, Neveu S, Louvard D, et al. (2008) Different
microtubule motors move early and late endocytic compartments. Traffic 9:
492–509.
44. Francis PT, Perry EK (2007) Cholinergic and other neurotransmitter
mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia
with Lewy bodies. Mov Disord 22 Suppl 17: S351–357.
45. Michel PP, Alvarez-Fischer D, Guerreiro S, Hild A, Hartmann A, et al. (2007)
Role of activity-dependent mechanisms in the control of dopaminergic neuron
survival. J Neurochem 101: 289–297.
46. Miller TM, Smith RA, Kordasiewicz H, Kaspar BK (2008) Gene-targeted
therapies for the central nervous system. Arch Neurol 65: 447–451.
47. Quik M, Bordia T, O’Leary K (2007) Nicotinic receptors as CNS targets for
Parkinson’s disease. Biochem Pharmacol 74: 1224–1234.
48. Wang Y, Yang PL, Tang JF, Lin JF, Cai XH, et al. (2008) Potassium channels:
possible new therapeutic targets in Parkinson’s disease. Med Hypotheses 71:
546–550.
49. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, et al. (2008) Prevalence of
vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease.
Arch Neurol 65: 1348–1352.
50. Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron
metabolism in Parkinson’s disease – ultrasonography as a biomarker. Neurotox
Res 9: 1–13.
51. Foglieni B, Ferrari F, Goldwurm S, Santambrogio P, Castiglioni E, et al. (2007)
Analysis of ferritin genes in Parkinson disease. Clin Chem Lab Med 45:
1450–1456.
52. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, et al. (2007)
Individual dopaminergic neurons show raised iron levels in Parkinson disease.
Neurology 68: 1820–1825.
53. Wallis LI, Paley MN, Graham JM, Grunewald RA, Wignall EL, et al. (2008)
MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn
Reson Imaging 28: 1061–1067.
54. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L (2004) Genetic
polymorphisms in Parkinson disease subjects with and without hallucinations: an
analysis of the cholecystokinin system. Arch Neurol 61: 1280–1284.
55. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular
markers of early Parkinson’s disease based on gene expression in blood. Proc
Natl Acad Sci U S A 104: 955–960.
56. Goedert M (2004) Tau protein and neurodegeneration. Semin Cell Dev Biol 15:
45–49.
57. Yi M, Stephens RM (2008) SLEPR: a sample-level enrichment-based pathway
ranking method – seeking biological themes through pathway-level consistency.
PLoS One 3: e3288.
58. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic
profiling of microRNA and messenger RNA reveals deregulated microRNA
expression in prostate cancer. Cancer Res 68: 6162–6170.
59. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, et al. (2008) A stromal
gene signature associated with inflammatory breast cancer. Int J Cancer 122:
1324–1332.
60. Dave UP, Akagi K, Tripathi R, Cleveland SM, Thompson MA, et al. (2009)
Murine leukemias with retroviral insertions at Lmo2 are predictive of the
leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS
Genet 5: e1000491.
61. Fatima N, Yi M, Ajaz S, Stephens RM, Stauffer S, et al. (2008) Altered gene
expression profiles define pathways in colorectal cancer cell lines affected by
celecoxib. Cancer Epidemiol Biomarkers Prev 17: 3051–3061.
62. Jiang H, Patel JJ, Yi M, Mu J, Ding J, et al. (2008) Genome-wide compensatory
changes accompany drug- selected mutations in the Plasmodium falciparum crt
gene. PLoS One 3: e2484.
63. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, et al. (2009) Differences
in the tumor microenvironment between African-American and European-
American breast cancer patients. PLoS One 4: e4531.
64. Nyswaner KM, Checkley MA, Yi M, Stephens RM, Garfinkel DJ (2008)
Chromatin-associated genes protect the yeast genome from Ty1 insertional
mutagenesis. Genetics 178: 197–214.
65. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, et al. (2008) Expression
of microRNAs and protein-coding genes associated with perineural invasion in
prostate cancer. Prostate 68: 1152–1164.
66. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, et al. (2008) Tumor
immunobiological differences in prostate cancer between African-American and
European-American men. Cancer Res 68: 927–936.
Gender and Transcriptome in PD
PLoS ONE | www.plosone.org 14 January 2010 | Volume 5 | Issue 1 | e8856